The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction.

Cardiovasc Diabetol · 2025 · PMC12023568 · PMID 40281528

Europe PMC DOI

hedged sentence

0.0860

closest p · 1.7× alpha

0.0860

boldest claim

The sentences

a decreasing trendp = 0.086so close (0.05 < p ≤ 0.1)

The effect of SNP on CVC did not significantly change after 3 months of empagliflozin treatment, but showed a decreasing trend (0.75 ± 0.23 vs. 0.65 ± 0.21, p = 0.086) (Table 2 ; Fig. 3 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.